Advertisement

Topics

Halozyme Therapeutics Company Profile

07:45 EDT 25th September 2017 | BioPortfolio

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's first hyaluronidase enzyme, recombinant human PH20 or rHuPH20, is the platform for three different products, including a medical device, a drug enhancement agent, and a therapeutic biologic. The company's initial products are being developed to offer safer and purer alternatives to existing slaughterhouse-derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine

Contact

Phone: 858.794.8889
Email: dramsay@halozyme.com


News Articles [1589 Associated News Articles listed on BioPortfolio]

Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference

SAN DIEGO, May 31, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7, 2012 at 12:30 ...

Halozyme Therapeutics to Present at the 31st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 3, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 201...

Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March

SAN DIEGO, March  7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the following two investor conferences in March: 24th Annual Roth Conference in...

Halozyme Therapeutics To Present At Upcoming Healthcare Conference

SAN DIEGO, Aug. 4, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting at the Canacco...

BMS inks $105m deal to access Halozyme drug delivery tech

Bristol-Myers Squibb will also make up to $160m in milestone payments for each candidate developed using Halozyme Therapeutics’ large-volume biologics delivery platform.

Bristol-Myers Squibb and Halozyme Enter Collaboration and License Agreement for ENHANZE Technology

NEW YORK & SAN DIEGO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced a global collaboration and license agreement...

Dividendenperle Roche: Neuer Deal mit Halozyme - jetzt zugreifen?

Seit 2006 arbeiten Roche mit der Biotech-Firma Halozyme Therapeutics aus San Diego zusammen. Im Rahmen dieser Kooperation konnte bereits ein Verabreichungsgerät für diverse Krebsmedikamente entwick....

Roche schliesst Lizenzabkommen mit Halozyme Therapeutics

So habe man eine weitere seiner "Enhance"-Technologien an Roche auslizensiert, wie das Biotechunternehmen am Donnerstag mitteilt. Dafür erhält Halozyme eine Einmalzahlung von 30 Mio USD von Roche. ....

Clinical Trials [117 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1147 Associated Companies listed on BioPortfolio]

Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery m...

Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalm...

Baxter International Inc. and Halozyme Therapeutics, Inc.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cance...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Halozyme Therapeutics" on BioPortfolio

We have published hundreds of Halozyme Therapeutics news stories on BioPortfolio along with dozens of Halozyme Therapeutics Clinical Trials and PubMed Articles about Halozyme Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Halozyme Therapeutics Companies in our database. You can also find out about relevant Halozyme Therapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record